- Incyte Corporation INCY announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (formerly INCB54707), an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa (HS).
- The study previously met its primary endpoint, demonstrating that at Week 16 – patients receiving povorcitinib once daily (QD) had significantly greater decreases from baseline in Abscess and Inflammatory Nodule (AN) count versus placebo.
- Related: Incyte Q4 Earnings Beat Street View, But Guidance Is Conservative Says Analyst.
- Results at Week 52, which include the 36-week open-label extension period during which all patients received povorcitinib 75 mg QD, show that average efficacy was sustained for all treatment arms following the switch to povorcitinib 75 mg QD.
- Povorcitinib also demonstrated durable efficacy at Week 52 in high-threshold outcomes, as evidenced by 22-29% of patients achieving HS Clinical Response 100 (HiSCR100).
- Price Action: INCY shares are down 0.98% at $80.44 on the last check Friday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
